The Potential Effects of Aliskiren on Atrial Remodeling Induced by Chronic Intermittent Hypoxia in Rats

References

• SchottenU, VerheuleS, KirchhofP, GoetteA. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325. doi:10.1152/physrev.00031.200921248168
   PubMed Web of Science ®Google Scholar
• ScridonA, ŞerbanRC, ChevalierP. Atrial fibrillation: neurogenic or myogenic? Arch Cardiovasc Dis. 2018;111(1):59–69. doi:10.1016/j.acvd.2017.11.00129229215
   PubMed Web of Science ®Google Scholar
• KonnoS, HirookaY, KishiT, SunagawaK. Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. J Hypertens. 2012;30(10):1992–1999. doi:10.1097/HJH.0b013e328357fa9822902874
   PubMed Web of Science ®Google Scholar
• JalifeJ, KaurK. Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015;25(6):475–484. doi:10.1016/j.tcm.2014.12.01525661032
   PubMed Web of Science ®Google Scholar
• LatinaJM, EstesNAM, GarlitskiAC, et al. The relationship between obstructive sleep apnea and atrial fibrillation: a complex interplay. Pulm Med. 2013;2013:1–11. doi:10.1155/2013/621736
   Google Scholar
• GeovaniniGR, Lorenzi-FilhoG. Cardiac rhythm disorders in obstructive sleep apnea. J Thorac Dis. 2018;10(Suppl 34):S4221–S4230. doi:10.21037/jtd.2018.12.6330687538
   PubMed Web of Science ®Google Scholar
• HohlM, LinzB, BohmM, et al. Sleep apnea and atrial arrhythmogenesis. Curr Cardiol Rev. 2014;10:362–368. doi:10.2174/1573403X100414070712513725004989
   PubMedGoogle Scholar
• Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm 2012;9:321–327. doi:10.1016/j.hrthm.2011.10.017
   Google Scholar
• Ma ZW, Zhang K, Wang WD, et al. [Tolvaptan attenuates atrial remodeling in rats undergoing chronic intermittent hypoxia via miRNA-21]. Zhonghua Xin Xue Guan Bing Za Zhi 2019;47(8):614–621. Chinese. doi:10.3760/cma.j.issn.0253-3758.2019.08.005
   Google Scholar
• YongjunQ, HuanzhangS, WenxiaZ, HongT, XijunX. From changes in local RAAS to structural remodeling of the left atrium: a beautiful cycle in atrial fibrillation. Herz. 2015;40(3):514–520. doi:10.1007/s00059-013-4032-724441392
   PubMed Web of Science ®Google Scholar
• PoolJL, SchmiederRE, AziziM, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11–20. doi:10.1016/j.amjhyper.2006.06.00317198906
   PubMed Web of Science ®Google Scholar
• Altarejo MarinT, Machado BertassoliB, Alves de Siqueira de CarvalhoA, FederD. The use of aliskiren as an antifibrotic drug in experimental models: A systematic review. Drug Dev Res. 2020;81(1):114–126. doi:10.1002/ddr.2161031605544
   PubMed Web of Science ®Google Scholar
• ZhaoZ, WangX, LiJ, et al. Protective effects of aliskiren on atrial ionic remodeling in a canine model of rapid atrial pacing. Cardiovasc Drugs Ther. 2014;28(2):137–143. doi:10.1007/s10557-014-6509-x24488001
   PubMed Web of Science ®Google Scholar
• YueL, FengJ, LiGR, NattelS. Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol. 1996;270(6 Pt 2):H2157–H2168. doi:10.1152/ajpheart.1996.270.6.H21578764269
   PubMed Web of Science ®Google Scholar
• LiD, MelnykP, FengJ, et al. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101(22):2631–2638. doi:10.1161/01.CIR.101.22.263110840016
   PubMed Web of Science ®Google Scholar
• CammAJ, KirchhofP, LipGY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–1420.20876603
   PubMed Web of Science ®Google Scholar
• PellmanJ, LyonRC, SheikhF. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol. 2010;48(3):461–467. doi:10.1016/j.yjmcc.2009.09.00119751740
   PubMed Web of Science ®Google Scholar
• GumprechtJ, DomekM, LipGYH, ShantsilaA. Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. J Hum Hypertens. 2019;33(12):824–836. doi:10.1038/s41371-019-0279-731690818
   PubMed Web of Science ®Google Scholar
• ZhangK, ZhaoL, MaZ, et al. Doxycycline attenuates atrial remodeling by interfering with microRNA-21 and downstream phosphatase and tensin homolog (PTEN)/Phosphoinositide 3-Kinase (PI3K) signaling pathway. Med Sci Monit. 2018;24:5580–5587. doi:10.12659/MSM.90980030098136
   PubMed Web of Science ®Google Scholar
• GoudisCA, KetikoglouDG. Obstructive sleep and atrial fibrillation: pathophysiological mechanisms and therapeutic implications. Int J Cardiol. 2017;230:293–300. doi:10.1016/j.ijcard.2016.12.12028040290
   PubMed Web of Science ®Google Scholar
• ZhangK, MaZ, WangW, et al. Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats. Cardiovasc Ther. 2018;36(6):e12466. doi:10.1111/1755-5922.1246630203914
   PubMed Web of Science ®Google Scholar
• NussbergerJ, WuerznerG, JensenC, BrunnerHR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39(1):E1–E8. doi:10.1161/hy0102.10229311799102
   PubMed Web of Science ®Google Scholar
• SolomonSD, AppelbaumE, ManningWJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–537. doi:10.1161/CIRCULATIONAHA.108.82621419153265
   PubMed Web of Science ®Google Scholar
• YeY, QianJ, CastilloAC, Perez-PoloJR, BirnbaumY. Aliskiren and valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011;25(6):505–515. doi:10.1007/s10557-011-6339-z21987107
   PubMed Web of Science ®Google Scholar
• ZhaoZ, ChenY, LiW, et al. Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(8):863–871. doi:10.1007/s00210-016-1249-z27118660
   PubMed Web of Science ®Google Scholar
• NattelS, HaradaM. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335–2345. doi:10.1016/j.jacc.2014.02.55524613319
   PubMed Web of Science ®Google Scholar
• NattelS, DobrevD. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33(15):1870–1877. doi:10.1093/eurheartj/ehs07922507975
   PubMed Web of Science ®Google Scholar
• QiXY, YehYH, XiaoL, et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res. 2008;103(8):845–854. doi:10.1161/CIRCRESAHA.108.17546318723446
   PubMed Web of Science ®Google Scholar
• EscandeD, CoulombeA, FaivreJF, DeroubaixE, CoraboeufE. Two types of transient outward currents in adult human atrial cells. Am J Physiol. 1987;252(1 Pt 2):H142–H148. doi:10.1152/ajpheart.1987.252.1.H1423028160
   PubMed Web of Science ®Google Scholar
• PatinoGA, IsomLL. Electrophysiology and beyond: multiple roles of Na+ channel β subunits in development and disease. Neurosci Lett. 2010;486(2):53–59. doi:10.1016/j.neulet.2010.06.05020600605
   PubMed Web of Science ®Google Scholar
• HayashiK, TadaH, YamagishiM. The genetics of atrial fibrillation. Curr Opin Cardiol. 2017;32(1):10–16. doi:10.1097/HCO.000000000000035627861186
   PubMed Web of Science ®Google Scholar
• Ziyadeh-IsleemA, ClatotJ, DuchateletS, et al. A truncating SCN5A mutation combined with genetic variability causes sick sinus syndrome and early atrial fibrillation. Heart Rhythm. 2014;11(6):1015–1023. doi:10.1016/j.hrthm.2014.02.02124582607
   PubMed Web of Science ®Google Scholar
• ZhangK, MaZ, SongC, DuanX, YangY, LiG. Role of ion channels in chronic intermittent hypoxia-induced atrial remodeling in rats. Life Sci. 2020;254:117797. doi:10.1016/j.lfs.2020.11779732417371
   PubMed Web of Science ®Google Scholar
• LiuC, LiuR, FuH, et al. Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. Cardiovasc Ther. 2017;35(5):e12284. doi:10.1111/1755-5922.12284
   Web of Science ®Google Scholar
• VoigtN, DobrevD. Atrial-Selective Potassium Channel Blockers. Card Electrophysiol Clin. 2016;8(2):411–421. doi:10.1016/j.ccep.2016.02.00527261831
   PubMedGoogle Scholar
• FordJ, MilnesJ, El HaouS, et al. The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation. Heart Rhythm. 2016;13(2):555–564. doi:10.1016/j.hrthm.2015.10.00326455450
   PubMed Web of Science ®Google Scholar